Spark Therapeutics to Participate in Multiple Upcoming Conferences

PHILADELPHIA, Oct. 31, 2016 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following upcoming conferences:

Genome Editing for Gene and Cell Therapy, a Herrenhausen Symposium, at the Herrenhausen Palace Conference Center in Hanover, Germany

• Katherine High, M.D., president and chief scientific officer, will participate in a panel discussion entitled “Therapeutics” on Thursday, Nov. 3, at 2:15 p.m. CET, and will give a presentation entitled “AAV-Mediated Gene Therapy for Genetic Disease” on Friday, Nov. 4 at 3:45 p.m. CET

Oxford Global 2^nd Annual Cell & Gene Therapy Congress, at the Radisson Blue in London

• Fraser Wright, Ph.D., chief technology officer, will give a presentation entitled “AAV Gene Therapy Vector Development to Support Clinical Program Advancement,” on Friday, Nov. 4, at 1:30 p.m. GMT

Credit Suisse 25^th Annual Healthcare Conference, at The Phoenician in Scottsdale, AZ

• Jeffrey D. Marrazzo, chief executive officer, will present on Tuesday, Nov. 8, at 1:30 p.m. MST

NEI/FDA Endpoints Workshop, at the Lister Hill Center – NIH Campus, in Bethesda, MD

• Albert M. Maguire, M.D., professor of ophthalmology at the Perelman School of Medicine of the University of Pennsylvania and principal investigator in the clinical trials of Spark Therapeutics’ investigational therapy voretigene neparvovec, will give a presentation entitled “Endpoints for Gene Therapy Clinical Trials – Low Luminance Mobility Maze”, on Wednesday, Nov. 9, at 2:05 p.m. EST

Retina International Interdisciplinary Open Workshop, at the National 4-H Conference Center, in Chevy Chase, MD

• Daniel Chung, D.O., clinical ophthalmic lead, will give a presentation entitled, “Maze test in ultra-low vision”, on Thursday, Nov. 10, at 10:25 a.m. EST

Stifel 2016 Healthcare Conference, at the Lotte New York Palace Hotel in New York City

• Stephen Webster, chief financial officer, will present on Wednesday, Nov. 16, at 3 p.m. EST

Jefferies 2016 London Healthcare Conference, at Waldorf Hilton in London

• Stephen Webster, chief financial officer, will present on Thursday, Nov. 17, at 8 a.m. GST

About Spark Therapeutics
Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-mediated diseases such as hemophilia, and neurodegenerative diseases. Spark Therapeutics’ validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Spark Therapeutics has reported top-line results from a pivotal Phase 3 clinical trial for its most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65), a potential treatment of a rare genetic blinding condition. Voretigene neparvovec has received both breakthrough therapy and orphan product designations. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B being developed under a collaboration with Pfizer and SPK-8011, a preclinical candidate for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more, please visit www.sparktx.com.

Spark Therapeutics Corporate Contacts:
Stephen W. Webster 			
Chief Financial Officer 			
Daniel Faga 				
Chief Business Officer			
(855) SPARKTX (1-855-772-7589)

Media Contact:
Dan Quinn
Ten Bridge Communication
(781) 475-7974
[email protected]